Exchange: NASDAQ·Updated 07:30 PM EDT
News
all
press releases
Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial
Atea Pharmaceuticals announced positive Phase 3 C-BEYOND trial results for its oral hepatitis C combination therapy vs. Gilead's therapy.read more...
Benzinga
More News
Atea Pharmaceuticals (AVIR) Upgraded to Buy: Here's What You Should Know
Atea Pharmaceuticals (AVIR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?
Here is how Atea Pharmaceuticals, Inc. (AVIR) and Design Therapeutics, Inc. (DSGN) have performed compared to their sector so far this year.
Zacks
Down 25% in 4 Weeks, Here's Why Atea Pharmaceuticals (AVIR) Looks Ripe for a Turnaround
Atea Pharmaceuticals (AVIR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Zacks
Atea Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript
read more...
Benzinga
Atea Pharmaceuticals (AVIR) Expected to Announce Quarterly Earnings on Tuesday
Atea Pharmaceuticals (NASDAQ:AVIR) will be releasing its Q1 2026 earnings after the market closes on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-atea-pharmaceuticals-inc-stock...
MarketBeat
Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price Up 1.6% - Still a Buy?
Atea Pharmaceuticals (NASDAQ:AVIR) Shares Up 1.6% - Time to Buy...
MarketBeat
Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price Up 5.9% - Here's Why
Atea Pharmaceuticals (NASDAQ:AVIR) Shares Up 5.9% - Time to Buy...
MarketBeat
Atea Pharmaceuticals (NASDAQ:AVIR) Hits New 12-Month High - Here's Why
Atea Pharmaceuticals (NASDAQ:AVIR) Hits New 1-Year High - What's Next...
MarketBeat
Atea Pharmaceuticals Q4 Earnings Call Highlights
Atea Pharmaceuticals (NASDAQ:AVIR) outlined progress in its hepatitis C (HCV) late-stage development program and provided an update on its newly expanded hepatitis E virus (HEV) pipeline during its...
MarketBeat

Advertisement|Remove ads.